Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms

被引：18

作者：

Mody R.M. ^{[1
]}

Erwin D.P. ^{[1
]}

Summers A.M. ^{[1
]}

Carrero H.A. ^{[1
]}

Selby E.B. ^{[1
]}

Ewell A.J. ^{[1
]}

Moran K.A. ^{[1
,2
]}

机构：

[1] Walter Reed Army Medical Center, Washington

[2] Uniformed Services University of the Health Sciences, Bethesda

来源：

Annals of Clinical Microbiology and Antimicrobials | / 6卷 / 1期

关键词：

Minimum Inhibitory Concentration; Clinical Isolate; Imipenem; Meropenem; Carbapenems;

D O I：

10.1186/1476-0711-6-6

中图分类号：

学科分类号：

摘要：

Background: Infections caused by multiply drug resistant organisms such as extended spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae are increasing. Carbapenems (imipenem and meropenem) are the antibiotics commonly used to treat these agents. There is limited clinical data regarding the efficacy of the newest carbapenem, ertapenem, against these organisms. Ertapenem susceptibility of ESBL-producing E. coli and K. pneumoniae clinical isolates were evaluated and compared to imipenem to determine if imipenem susceptibility could be used as a surrogate for ertapenem susceptibility. Methods: 100 ESBL isolates (n = 34 E. coli and n = 66 K. pneumoniae) collected from 2005-2006 clinical specimens at WRAMC were identified and tested for susceptibility by Vitek Legacy [bioMerieux, Durham, NC]. Ertapenem susceptibility was performed via epsilometer test (E-test) [AB Biodisk, Solna, Sweden]. Results: 100% of ESBL isolates tested were susceptible to ertapenem. 100% of the same isolates were also susceptible to imipenem. Conclusion: These results, based on 100% susceptibility, suggest that ertapenem may be an alternative to other carbapenems for the treatment of infections caused by ESBL-producing E. coli and K. pneumoniae. Clinical outcomes studies are needed to determine if ertapenem is effective for the treatment of infection caused by these organisms. However, due to lack of resistant isolates, we are unable to conclude whether imipenem susceptibility accurately predicts ertapenem susceptibility. © 2007 Mody et al; licensee BioMed Central Ltd.

引用

共 13 条

[1]

Aronson N., Sanders J., Moran K., In Harm's Way: Infections in Deployed American Military Forces, Clin Inf Dis, 43, pp. 1045-1051, (2006)

[2]

Rupp M., Fey P., Extended Spectrum B-lactamase (ESBL)-Producing Enterobacteriaceae: Considerations for Diagnosis, Prevention, and Drug Treatment, Drugs, 63, pp. 353-365, (2003)

[3]

Colodner R., Raz R., Extended-Spectrum Beta-Lactamases: The End of Cephalosporins?, IMAJ, 7, pp. 336-338, (2005)

[4]

Jacoby G., Munoz-Price L., Mechanisms of Disease: The New (beta)-Lactamases, N Eng J Med, 352, pp. 380-391, (2005)

[5]

Ramphal R., Ambrose P., Extended-Spectrum B-Lactamases and Clinical Outcomes: Current Data, Clin Inf Dis, 42, (2006)

[6]

Betriu C., Salso S., Sancez A., Culebras E., Gomez M., Rodriguez-Avial I., Picazo J., Comparative in vitro activity and the inoculum effect of ertapenem against Enterobacteriaceae resistant to extended-spectrum cephalosporins, Int J Antimicrob Agents, 28, pp. 1-5, (2006)

[7]

Livermore D., Oakton K., Carter M., Warner M., Activity of Ertapenem (MK-0826) versus Enterobacteriaceae with Potent B-Lactamases, Antimicrob Agents Chemother, 45, pp. 2831-2837, (2001)

[8]

Performance Standard for Antimicrobial Susceptibility Testing. 16th Informational supplement, (2006)

[9]

AB BIODISK, (2006)

[10]

Elliott E., Brink A., van Greune J., Els Z., Woodford N., Turton J., Warner M., Livermore D.M., In Vivo Development of Ertapenem Resistance in a Patient with Pneumonia Caused by Klebsiella pneumoniae with an Extended-Spectrum B-lactamase, Clin Inf Dis, 42, (2006)

← 1 2 →